JP2001504215A - 非変性界面活性剤を使用する自動分析器におけるプローブのコーティングの防止 - Google Patents
非変性界面活性剤を使用する自動分析器におけるプローブのコーティングの防止Info
- Publication number
- JP2001504215A JP2001504215A JP51343298A JP51343298A JP2001504215A JP 2001504215 A JP2001504215 A JP 2001504215A JP 51343298 A JP51343298 A JP 51343298A JP 51343298 A JP51343298 A JP 51343298A JP 2001504215 A JP2001504215 A JP 2001504215A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- assay
- probe
- surfactant
- denaturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 title claims abstract description 90
- 239000004094 surface-active agent Substances 0.000 title claims abstract description 62
- 238000000576 coating method Methods 0.000 title claims abstract description 44
- 239000011248 coating agent Substances 0.000 title claims abstract description 43
- 230000002265 prevention Effects 0.000 title description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 144
- 238000003556 assay Methods 0.000 claims abstract description 127
- 238000000034 method Methods 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 71
- 239000000126 substance Substances 0.000 claims abstract description 44
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 40
- 239000003599 detergent Substances 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 9
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 59
- 210000001685 thyroid gland Anatomy 0.000 claims description 38
- 102000014914 Carrier Proteins Human genes 0.000 claims description 32
- 108091008324 binding proteins Proteins 0.000 claims description 32
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 18
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 17
- 229940034208 thyroxine Drugs 0.000 claims description 17
- 229940035722 triiodothyronine Drugs 0.000 claims description 13
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 10
- 239000003945 anionic surfactant Substances 0.000 claims description 8
- 239000003093 cationic surfactant Substances 0.000 claims description 8
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000006249 magnetic particle Substances 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 108010074605 gamma-Globulins Proteins 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims description 4
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 claims description 4
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 4
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 4
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 4
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 3
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 3
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 3
- 229940099347 glycocholic acid Drugs 0.000 claims description 3
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims description 2
- 229910052776 Thorium Inorganic materials 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical class C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000002731 protein assay Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101000633632 Homo sapiens Teashirt homolog 3 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102100029222 Teashirt homolog 3 Human genes 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- -1 cell Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D2111/00—Cleaning compositions characterised by the objects to be cleaned; Cleaning compositions characterised by non-standard cleaning or washing processes
- C11D2111/40—Specific cleaning or washing processes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/11—Automated chemical analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アッセイの間の自動分析器のプローブへの疎水性物質のコーティングを、防 止するまたは減少させるための方法であって、以下の工程: プローブを有する自動分析器を提供する工程; アッセイで使用するための非変性界面活性剤および試薬を含有する組成 物を提供する工程であって、該非変性界面活性剤が、アッセイの間の疎水性物質 での該プローブのコーティングを防止または減少し得る工程;および アッセイの間に該プローブと該組成物とを接触させる工程であって、そ の結果、該疎水性物質での該プローブのコーティングが防止または減少される、 工程 を包含する、方法。 2.請求項1に記載の方法であって、前記非変性界面活性剤がアニオン性界面活 性剤である、方法。 3.請求項1に記載の方法であって、前記非変性界面活性剤が双性イオン性界面 活性剤である、方法。 4.請求項1に記載の方法であって、前記非変性界面活性剤がカチオン性界面活 性剤である、方法。 5.請求項1に記載の方法であって、前記非変性界面活性剤がコール酸ナトリウ ムである、方法。 6.請求項1に記載の方法であって、前記非変性界面活性剤がコール酸ナトリウ ムのアナログである、方法。 7.請求項1に記載の方法であって、前記非変性界面活性剤が、デオキシコール 酸、グリココール酸、リトコール酸、タウロコール酸、CHAPS、CHAPSO、それら のナトリウム塩誘導体、およびそれらの混合物からなる群より選択される、方法 。 8.請求項1に記載の方法であって、前記組成物中の前記非変性界面活性剤の濃 度が、約0.01%〜約10%である、方法。 9.請求項1に記載の方法であって、前記非変性界面活性剤の濃度が、約0.1% 〜約3%である、方法。 10.請求項1に記載の方法であって、前記組成物中の前記非変性界面活性剤の 濃度が、約0.01%〜約1%である、方法。 11.請求項1に記載の方法であって、前記試薬が、血清または血漿中の不飽和 甲状腺結合タンパク質をアッセイするためのものである、方法。 12.請求項11に記載の方法であって、前記試薬が標識化トリヨードサイロニ ン−ウシγグロブリンおよび未標識のトリヨードサイロニンを含有する、方法。 13.請求項11に記載の方法であって、前記試薬が、磁性粒子に結合された抗 トリヨードサイロニン抗体を含有する、方法。 14.請求項11に記載の方法であって、前記試薬が、標識化チロキシン−ウシ γグロブリンおよび未標識のチロキシンを含有する、方法。 15.請求項11に記載の方法であって、前記試薬が磁性粒子に結合された抗チ ロキシン抗体を含有する、方法。 16.請求項11に記載の方法であって、前記疎水性物質がトリヨードサイロニ ンである、方法。 17.請求項11に記載の方法であって、前記疎水性物質がチロキシンである、 方法。 18.自動分析器のランダムアクセス様式を使用してアッセイを行うための方法 であって、以下の工程: プローブおよびランダムアクセス様式を有する自動分析器を提供する工 程、 アッセイで使用するための非変性界面活性剤および試薬を含有する組成 物を提供する工程であって、該非変性界面活性剤が、アッセイを行う場合、該疎 水性物質での該プローブのコーティングを防止または減少し得る、工程;および 該自動分析器のランダムアクセス様式を用いてアッセイを行う工程、 を包含する、方法。 19.請求項18に記載の方法であって、前記アッセイが、血清または血漿中の 不飽和甲状腺結合タンパク質の評価である、方法。 20.血清または血漿中の不飽和甲状腺結合タンパク質を評価するためのアッセ イの間の、自動分析器のプローブ上への疎水性物質のコーティングを防止するま たは減少することにおいて使用するための組成物であって、アッセイで使用する ための、アニオン性界面活性剤、カチオン性界面活性剤、双性イオン性界面活性 剤、およびそれらの混合物からなる群より選択される、非変性界面活性剤;およ び試薬を含有する、組成物。 21.請求項20に記載の組成物であって、前記界面活性剤がコール酸ナトリウ ム、コール酸ナトリウムのアナログ、およびそれらの混合物からなる群より選択 される物質を含有する、組成物。 22.請求項20に記載の組成物であって、前記試薬が標識化トリヨードサイロ ニン−ウシγグロブリン、未標識のトリヨードサイロニン、抗トリヨードサイロ ニン抗体、標識化チロキシン、未標識のチロキシン、および抗チロキシン抗体か らなる群より選択される物質を含有する、組成物。 23.不飽和甲状腺結合タンパク質をアッセイすることにおいて使用される試薬 の安定性を増強するための方法であって、以下の工程: 不飽和甲状腺結合タンパク質をアッセイすることにおいて使用するため の試薬を提供する工程; 該試薬の安定性を増強し得る非変性界面活性剤を含有する組成物を提供 する工程;および 該組成物と該試薬とを接触させる工程であって、その結果、該試薬の安 定性が増強される工程、 を包含する、方法。 24.請求項23に記載の方法であって、前記試薬が、標識化トリヨードサイロ ニン−ウシγグロブリンおよび未標識のトリヨードサイロニンを含有する、方法 。 25.請求項23に記載の方法であって、前記試薬が磁性粒子に結合された抗ト リヨードサイロニン抗体を含有する、方法。 26.請求項23に記載の方法であって、前記試薬が標識化チロキシン−ウシγ グロブリンおよび未標識のチロキシンを含有する、方法。 27.請求項23に記載の方法であって、前記試薬が磁性粒子に結合された抗チ ロキシン抗体を含有する、方法。 28.請求項23に記載の方法であって、前記非変性界面活性剤が、アニオン性 界面活性剤、双性界面活性剤、カチオン性界面活性剤、およびそれらの混合物か らなる群より選択される、方法。 29.請求項23に記載の方法であって、前記非変性界面活性剤が、コール酸ナ トリウム、コール酸ナトリウムのアナログ、およびそれらの混合物からなる群よ り選択される、方法。 30.請求項23に記載の方法であって、前記試薬のオンボード安定性が増強さ れる、方法。 31.請求項23に記載の方法であって、前記試薬の保存検量安定性が増強され る、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/712,829 | 1996-09-12 | ||
US08/712,829 US5786153A (en) | 1996-09-12 | 1996-09-12 | Prevention of probe coating on automated analyzers using a non-denaturing surfactant |
PCT/IB1997/001064 WO1998011441A1 (en) | 1996-09-12 | 1997-09-08 | Prevention of probe coating on automated analyzers using a non-denaturing surfactant |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504215A true JP2001504215A (ja) | 2001-03-27 |
JP3929499B2 JP3929499B2 (ja) | 2007-06-13 |
Family
ID=24863719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51343298A Expired - Lifetime JP3929499B2 (ja) | 1996-09-12 | 1997-09-08 | 非変性界面活性剤を使用する自動分析器におけるプローブのコーティングの防止 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5786153A (ja) |
EP (1) | EP0925507B1 (ja) |
JP (1) | JP3929499B2 (ja) |
AT (1) | ATE221205T1 (ja) |
AU (1) | AU3951697A (ja) |
DE (1) | DE69714272T2 (ja) |
DK (1) | DK0925507T3 (ja) |
ES (1) | ES2181018T3 (ja) |
PT (1) | PT925507E (ja) |
WO (1) | WO1998011441A1 (ja) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115313A (en) * | 1974-10-08 | 1978-09-19 | Irving Lyon | Bile acid emulsions |
EP0061541A1 (en) * | 1981-03-27 | 1982-10-06 | Biospecia Limited | Immunological analysis and a biochemical agent therefor |
US5512659A (en) * | 1989-08-04 | 1996-04-30 | Syntex (U.S.A.) Inc. | Compositions useful in heterogeneous immunoassays |
US5066336A (en) * | 1989-12-01 | 1991-11-19 | Akzo N.V. | Method for cleaning reagent delivery probes |
US5464749A (en) * | 1991-07-22 | 1995-11-07 | Bayer Corporation | Immunoassay of free substances in biological fluids |
US5395545A (en) * | 1993-10-21 | 1995-03-07 | Akzo N.V. | Cleaning solution for automated analyzers |
FR2715566B1 (fr) * | 1994-02-03 | 1996-03-08 | Synthelabo | Solutions aqueuses concentrées d'argatroban. |
US5888752A (en) * | 1995-05-16 | 1999-03-30 | Bayer Corporation | Universal rinse reagent and method for use in hematological analyses of whole blood samples |
-
1996
- 1996-09-12 US US08/712,829 patent/US5786153A/en not_active Expired - Lifetime
-
1997
- 1997-09-08 WO PCT/IB1997/001064 patent/WO1998011441A1/en active IP Right Grant
- 1997-09-08 AT AT97936825T patent/ATE221205T1/de not_active IP Right Cessation
- 1997-09-08 ES ES97936825T patent/ES2181018T3/es not_active Expired - Lifetime
- 1997-09-08 JP JP51343298A patent/JP3929499B2/ja not_active Expired - Lifetime
- 1997-09-08 EP EP97936825A patent/EP0925507B1/en not_active Expired - Lifetime
- 1997-09-08 PT PT97936825T patent/PT925507E/pt unknown
- 1997-09-08 AU AU39516/97A patent/AU3951697A/en not_active Abandoned
- 1997-09-08 DK DK97936825T patent/DK0925507T3/da active
- 1997-09-08 DE DE69714272T patent/DE69714272T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP3929499B2 (ja) | 2007-06-13 |
WO1998011441A1 (en) | 1998-03-19 |
DE69714272D1 (de) | 2002-08-29 |
AU3951697A (en) | 1998-04-02 |
ES2181018T3 (es) | 2003-02-16 |
DE69714272T2 (de) | 2002-11-14 |
US5786153A (en) | 1998-07-28 |
EP0925507B1 (en) | 2002-07-24 |
ATE221205T1 (de) | 2002-08-15 |
PT925507E (pt) | 2002-11-29 |
DK0925507T3 (da) | 2002-09-09 |
EP0925507A1 (en) | 1999-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7718380B2 (en) | Method of tacrolimus extraction and quantification using aqueous detergents | |
JP4972161B2 (ja) | タクロリムス標準物質及びそれを使用する方法 | |
CN101512342B (zh) | 用于测量分析物浓度的测定的稳定剂和捕获配体 | |
EP0133464B1 (en) | Iodothyronine immunoassays employing hms as tbp blocking agent | |
JP3560979B2 (ja) | 安定化された水性ステロイド免疫検定用標準 | |
JP3740898B2 (ja) | 生理活性成分の測定法 | |
CN112485418B (zh) | 一种用于人体维生素b12含量检测的释放剂及其应用 | |
Kane | Use of sodium salicylate as a blocking agent for cortisol-binding-globulin in a radioimmunoassay for cortisol on unextracted plasma | |
EP1064552B1 (en) | Immunoassays using casein coating of particles | |
JPH05203646A (ja) | 遊離種アナライト検定 | |
EP3865873A1 (en) | Method and assay reagent for immunoassay of leucine-rich ?2 glycoprotein | |
JP2001504215A (ja) | 非変性界面活性剤を使用する自動分析器におけるプローブのコーティングの防止 | |
CA2138536C (en) | Chemiluminescent assay for dsdna antibodies | |
JP3042753B2 (ja) | 解離剤を使用する免疫検定法 | |
JP3228791B2 (ja) | 検体中の抗原又は抗体の測定法 | |
US5597701A (en) | Process for determining androstenone contents in adipose tissues | |
JPH06102275A (ja) | ステロイドホルモンの測定方法 | |
JP2002365298A (ja) | 測定妨害を低減する方法及び試薬組成物 | |
GB2312746A (en) | Immunoassay for an analyte in a water immiscible solvent | |
AU665271B2 (en) | Immunological method of analyses | |
JP3401903B2 (ja) | ステロイド・ホルモンまたはビタミン類の測定法 | |
JP6210568B2 (ja) | 高精度な免疫学的測定法 | |
JP2000046829A (ja) | 生理活性成分の測定法 | |
CN117783544A (zh) | 用于睾酮检测的分析缓冲液和试剂盒 | |
CN114002442A (zh) | 睾酮检测试剂盒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061206 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070307 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100316 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110316 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110316 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120316 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130316 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130316 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140316 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |